Rennova Health (RNVA) Stock Price, News & Analysis

Company Overview

Rennova Health, Inc. is a diversified healthcare company organized around three core business segments: Bioscience, Medical Devices and Specialty Pharmaceutical Distribution. Through its Bioscience division, Rennova develops and commercializes molecular diagnostic platforms, reagent kits and point‐of‐care testing solutions that address infectious diseases, genetic markers and metabolic conditions. The company’s in‐house research and development teams focus on assay design, validation and partnering with laboratories to accelerate the adoption of rapid‐testing protocols.

In its Medical Devices segment, Rennova Health manufactures and supplies a range of vascular access products, fluid management systems and catheterization supplies. These devices are used in hospital, ambulatory surgical center and long‐term care settings, supporting intravenous therapy, blood collection and hemodynamic monitoring. The company leverages contract manufacturing relationships and an established supply chain network to serve customers across all 50 U.S. states.

The Specialty Pharmaceutical Distribution arm of Rennova Health supplies generic injectable drugs, personal protective equipment and infection prevention products to healthcare providers and wholesalers. This segment emphasizes scalable logistics, cold‐chain management and regulatory compliance to ensure consistent product availability in critical care environments. In recent years, the company has expanded its distribution footprint into Canada and select European markets through strategic partnerships.

Founded in the early 2000s and headquartered in Birmingham, Alabama, Rennova Health is led by President and Chief Executive Officer Kenneth Berenger, who brings more than two decades of experience in medical device and diagnostic industries. The executive team comprises industry veterans in finance, regulatory affairs and commercial operations, supporting the company’s mission to deliver innovative healthcare solutions with a focus on quality, affordability and patient outcomes.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1.90 million shs
• Average Volume: 1.15 million shs
• Market Capitalization: $4.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RNVA Stock Analysis - Frequently Asked Questions

How were Rennova Health's earnings last quarter?

Rennova Health, Inc. (OTCMKTS:RNVA) released its quarterly earnings data on Tuesday, August, 14th. The company reported $2,500,000,000.00 EPS for the quarter. The company had revenue of $3.29 million for the quarter.

When did Rennova Health's stock split?

Shares of Rennova Health reverse split on Wednesday, March 16th 2022.The 1-10000 reverse split was announced on Wednesday, March 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of Rennova Health?

Shares of RNVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rennova Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rennova Health investors own include Neovasc (NVCN), Himax Technologies (HIMX), LadRx (CYTR), NightHawk Biosciences (NHWK), Precipio (PRPO), 22nd Century Group (XXII) and Biopharmx (BPMX).

Company Calendar

• Last Earnings: 8/14/2018
• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Healthcare
• Current Symbol: OTCMKTS:RNVA
• Previous Symbol: NASDAQ:RNVA
• CIK: 931059
• Web: www.rennovahealth.com
• Phone: 561-855-1626
• Fax: 415-248-5351
• Employees: 60
• Year Founded: 1995

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $18.69 million
• Price / Sales: 0.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 43,051,320,000
• Free Float: 34,350,651,000
• Market Cap: $4.31 million
• Optionable: Not Optionable
• Beta: 17.59